Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia

@article{Frnberg2007AsenapineAN,
  title={Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia},
  author={O. Fr{\aa}nberg and C. Wiker and M. Marcus and {\AA}. Konradsson and K. Jardemark and B. Schilstr{\"o}m and M. Shahid and E. Wong and T. Svensson},
  journal={Psychopharmacology},
  year={2007},
  volume={196},
  pages={417-429}
}
RationaleAsenapine is a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder.Materials and methodsThe present study was undertaken to investigate the effects of asenapine using animal models predictive of antipsychotic efficacy (conditioned avoidance response [CAR]) and extrapyramidal side effects (EPS; catalepsy). In parallel, the effects of asenapine on regional dopamine output using in vivo microdialysis in freely moving rats, dopamine… Expand
Asenapine effects in animal models of psychosis and cognitive function
TLDR
At doses greater than those required for antipsychotic activity, asenapine impaired cognitive performance due to disturbance of motor function, an effect also observed with olanzapine and risperidone. Expand
The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania
TLDR
This review analyzes the pharmacological, neurochemical, behavioral, and molecular mechanisms of asenapine and their contribution to the beneficial therapeutic advantages of the drug as reported in published preclinical and clinical studies, product labels, and poster presentations. Expand
Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission
TLDR
The data suggest that adjunctive treatment with a NET inhibitor may enhance the therapeutic effect of low-dose olanzapine in schizophrenia without increasing EPS liability and add an antidepressant action, thus in principle allowing for a dose reduction of olanZapine with a concomitant reduction of dose-related side effects, such as EPS and weight gain. Expand
Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity
TLDR
Asenapine is capable of inducing a sensitization effect and a cross-sensitization to olanzapine and clozapine (to a lesser extent) and is suggested to resemble olanZapine to a greater extent in its therapeutic and side effect profiles. Expand
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism
TLDR
A role for D1 but not 5-HT1A receptor mechanisms in mediating the cognitive effects of asenapine in this rodent model is demonstrated. Expand
Differential regional and dose-related effects of asenapine on dopamine receptor subtypes
TLDR
Results indicate that asenapine has region-specific and dose-dependent effects on dopamine receptor subtypes in rat forebrain, which may contribute to asenAPine’s unique psychopharmacological properties. Expand
Adjunctive Treatment with Asenapine Augments the Escitalopram-Induced Effects on Monoaminergic Outflow and Glutamatergic Neurotransmission in the Medial Prefrontal Cortex of the Rat
TLDR
The results support the notion that the augmentation of SSRIs by atypical antipsychotic drugs in treatment-resistant depression may, at least in part, be related to enhanced catecholamine output in the prefrontal cortex and that asenapine may be clinically used to achieve this end. Expand
Evaluation of the clinical efficacy of asenapine in schizophrenia
TLDR
Asenapine is a recently approved agent with an acceptable cardiometabolic profile and exhibits similar efficacy as other antipsychotic medications, primarily on positive symptoms of schizophrenia. Expand
Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain
TLDR
It is indicated that chronic treatment with asenapine has region‐specific and dose‐dependent effects on ionotropic Glu‐receptor subtypes in rat forebrain, which might contribute to the unique psychopharmacologic properties of asenAPine. Expand
Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions
TLDR
Asenapine can ameliorate mPFC lesion-induced impairment in attentional set-shifting, and is associated with a greater activation of the spared neurons in the anterior mP FC, suggesting that asenAPine may benefit impaired cognitive flexibility in disorders such as schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
TLDR
To support the contention that NMDA receptor antagonist administration represents a viable model of schizophrenia, the behavioral and neurobiological effects of these drugs are discussed, especially with regard to differing profiles following single-dose and long-term exposure. Expand
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability
TLDR
Catalepsy remains a suitable rodent model for detecting compounds with EPS liability in humans and the results with haloperidol and clozapine are consistent with the clinical effects of these drugs (severe versus mild EPS). Expand
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Risperidone and its active metabolite 9-OH-risperidone were compared to reference antipsychotic drugs (haloperidol, pipamperone, fluspirilene, clozapine, zotepine) and compounds under developmentExpand
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
TLDR
It is indicated that asenapine has a unique human receptor signature, with binding affinity and antagonistic properties that differ appreciably from those of antipsychotic drugs. Expand
Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
TLDR
Support is provided for the notion that 5-HT2 receptor antagonism may be of considerable significance for the action of atypical antipsychotic drugs on mesolimbocortical dopaminergic neurotransmission and for the selective action of systemically administered APZ on DA in the MPC. Expand
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
TLDR
Asenapine was effective and well tolerated in patients with acute schizophrenia and may provide a new option for control of negative symptoms. Expand
Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine
TLDR
The results suggest that clozapine's unique therapeutic profile may be related to its failure to induce Fos in the striatum as well as its idiosyncratic actions in the lateral septum and medial prefrontal cortex. Expand
Enhanced Cortical Dopamine Output and Antipsychotic-like Effect of Raclopride with Adjunctive Low-Dose L-dopa
TLDR
These data support the clinical observation that low-dose L-dopa might improve the effect of typical APDs in schizophrenia and indicate that increased prefrontal DA output per se enhances the antipsychotic effect of Typical APDs. Expand
Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
TLDR
In contrast to the regionally rather homogenous activation of brain DA systems caused by risperidone, the drug was found to enhance brain 5-HT metabolism preferentially in the MPC, as indicated by the elevated extracellular concentration of 5-HIAA in this region. Expand
Actions of ORG 5222 as a novel psychotropic agent
TLDR
It is concluded that ORG 5222 is effective to antagonise mesolimbic dopamine function in the rodent and primate and an aversive behaviour in rodent tests. Expand
...
1
2
3
4
5
...